Q-omics provides the consensus-scored GAPDHP16 profile across patient tissues and cancer cell-line models. GAPDHP16 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, GAPDHP16 is differentially expressed in 4, with the highest sampling consensus in HNSC. Additionally, GAPDHP16 RNA expression shows 7,363 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, HNSC, and LSCC as cancer lineages where GAPDHP16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GAPDHP16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GAPDHP16 survival associations across molecular data types. GAPDHP16 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GAPDHP16 RNA expression–survival associations across cancer types. High GAPDHP16 expression shows unfavorable associations in UVM, LUSC, DLBC, ACC and UCS, but favorable associations in COAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .006). Together, the overview and detailed table identify UVM as the clearest survival context for GAPDHP16 RNA expression.
This table summarizes GAPDHP16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for GAPDHP16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GAPDHP16 shows higher tumor expression in HNSC, LUSC, PRAD and THCA. The HNSC box plot shows higher GAPDHP16 RNA expression in tumor versus normal tissue (log2 FC = +0.021, t-test p = .002).
This table shows molecular features associated with GAPDHP16 in patient tissues and cancer cell lines. In patient samples, GAPDHP16 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
